DrugName: SC-0806
BioArctic AB, announced that the European Patent Office (EPO) has issued a decision to grant the company’s patent application in Europe, EP12815796.3, for a medical device, which is one of the main components in the product candidate SC0806. The product candidate is a combination of a medical device (implant) and a medicinal product (FGF1) for patients with complete spinal cord injury. The decision states that the European patent, EP 2 787 900 B1, will enter into force on October 24, 2018.
The patent will provide important protection for medical for treatment of patients with complete spinal cord injury. A corresponding patent has previously been granted in China and during 2018 in Australia, the US and Japan. BioArctic has an active patent strategy covering all major geographic markets, including the US, Japan, China and Europe.
”The patent protection in Europe is in line with the company’s strategy to protect important products through patents. A clinical Phase 1/2 study with the product candidate SC0806 for patients with complete spinal cord injury is currently ongoing. These patients lack effective treatment today. Our ambition is to develop SC0806 and thus improve the patients’ quality of life,” said Gunilla Osswald, CEO of BioArctic.
About SC0806
SC0806 is a novel product under development for the treatment for patients with Complete Spinal Cord Injury. The product candidate is currently in an ongoing Phase 1/2 clinical trial. The first patient was treated in 2016. The product candidate is a combination of a biodegradable medical device and a drug substance (FGF1) designed to support nerve regeneration across the injured area in the spinal cord.
The inclusion of patients with complete spinal cord injury in the first panel of BioArctic’s ongoing study was completed in April 2018. Due to the novelty of the treatment, patients have been included sequentially, in order to monitor the effect and safety. The last patient in the first panel has now received the treatment with SC0806, which completes the inclusion of patients into the first panel of three. The initiation of the next panel is ongoing. Each panel consists of six patients receiving SC0806 and three control patients. The treatment with SC0806 includes a surgical procedure. The surgery is followed by 18 months of intensive training in a robotic system to support nerve regeneration and muscle rebuilding in the part of the body affected by the paralysis. Patients receiving SC0806 are also given the option of 12 months additional participation in an extension study.
You can viagra buy germany web-site here even look out for Vardenafil online. Common risk factors for viagra online impotence are obesity, diabetes, hypertension and cardiovascular issue should not think of taking PDE-5 inhibitors or erection-boosting medicines without consulting a healthcare provider. However, if you go to a legal medication website, then ask them to send you an email message with an exciting subject that causes you to open it, and then there’s not deeprootsmag.org cheap super cialis much there, but by opening the email you’ve unleashed a Trojan horse that crawls out of the email and blasts the virus out to all of their computers (not a great way to win. Men suffer from impotence issues have got an effective remedy for calming anger, stress and anxiety. ordering viagra from india
The product obtained orphan drug designation in 2010 in EU and in 2011 in the US, which gives the company 10 and 7 years of market exclusivity in Europe and the US, respectively.
BioArctic has received funding from the European Union’s Horizon 2020 Research and Innovation Program under Grant Agreement No. 643853 to perform a clinical study with SC0806.
Key Facts
News Category Other Product News
Product Development
Intellectual Property
Company BioArctic AB
Country Europe > Sweden
Europe > Germany